You Position: Home > Paper
Differences in pain and inflammation between Diclofenac 0. 1％ and Nepafenac 0. 1％ after cataract surgery
( views:100, downloads:55 )
- Author:
- No author available
- Journal Title:
- International Eye Science
- Issue:
- 5
- DOI:
- 10.3980/j.issn.1672-5123.2019.5.03
- Key Word:
- 超声乳化术;老年性白内障;房水闪光细胞;双氯芬酸;奈帕芬胺
Abstract： 目的:比较白内障患者术前局部应用0.1％ 双氯芬酸与0.1％奈帕芬胺的疼痛度和抗炎疗效.方法:该前瞻性随机临床试验于2017/06-08在Dr.Yap眼科医院进行.共56例患者诊断为老年性白内障并接受超声乳化术,未出现并发症.受试者按术前应用滴眼剂分为两组(双氯芬酸组和奈帕芬胺组).炎症特征(第1,7和14d随访)如疼痛度、结膜充血、眼睑痉挛、房水闪辉和细胞水平为主要结果,而角膜内皮细胞密度和形态为次要观察结果.结果:术后1d(分别为P=0.284,效应量=0.29,95％CI=-0.09～0.31;P=0.254,效应量=0.31,95％CI=-0.13～0.49)和7d(P=1.000和P=0.556,效应量=0.18,95％CI=-0.08～0.16),两组间结膜充血和眼睑痉挛水平无统计学差异.奈帕芬胺组疼痛指数(术中及术后1、4d)显著低于双氯芬酸组(分别为P=0.006,效应量=0.77,95％CI=0.24～1.34;P=0.045,效应量=0.39, 95％CI=-0.10～0.62;P=0.014,效应量=0.69,95％CI=-0.06～0.50).术后1d奈帕芬胺组房水闪辉和细胞水平较低(P=0.029,效应量=0.59,95％CI=0.02～0.36).两组间角膜内皮密度降低无统计学差异,而术后7d奈帕芬胺组六角形细胞比例减少较多(P=0.042,效应量=-0.55,95％CI=-2.33～-0.03).结论:与双氯芬酸组相比,奈帕芬胺组疼痛度和房水闪辉细胞值较低.
- [1]Ribeiro MS,Scott IU,Messias A,etc.Comparison of corneal changes after phacoemulsification using BSS Plus versus Lactated Ringer's irrigating solution: a prospective randomised trial.[J].2011,95(4).
- [2]Murphy PJ,Lau JS,Sim MM,etc.How red is a white eye? Clinical grading of normal conjunctival hyperaemia.[J].2007,21(5).
- [3]Hoffman, Richard S.,Braga-Mele, Rosa,Donaldson, Kendall,etc.Cataract surgery and nonsteroidal antiinflammatory drugs[J].2016,42(9).
- [4]Sanduk Ruit,Geoffrey Tabin,David Chang,etc.A Prospective Randomized Clinical Trial of Phacoemulsification vs Manual Sutureless Small-Incision Extracapsular Cataract Surgery in Nepal[J].2007,143(1).
- [5]M, Nardi,C, Lobo,A, Bereczki,etc.Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery.[J].2007,1(4).
- [6]Roberts CW.Pretreatment with topical diclofenac sodium to decrease postoperative inflammation.[J].1996,103(4).
- [7]Mead D,Coll AM,Ameen JR.Postoperative pain assessment tools in day surgery: literature review.[J].2004,46(2).
- [8]Storr-Paulsen T,Storr-Paulsen A,Norregaard JC,etc.Endothelial cell damage after cataract surgery: divide-and-conquer versus phaco-chop technique.[J].2008,34(6).
- [9]Holland EJ,Lane SS,Lehmann RP,etc.Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery.[J].2007,33(1).
- [10]J, Jankovic,J, Orman.Blepharospasm: demographic and clinical survey of 250 patients.[J].1984,16.
- [11]Chalkley TH,Duong HV,Westfield KC.Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.[J].2007,33(11).
- [12]Bruce I, Gaynes,Anne, Onyekwuluje.Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension.[J].2008,2(2).
- [13]Anders N,Walkow T,Klebe S.Endothelial cell loss after phacoemulsification: relation to preoperative and intraoperative parameters.[J].2000,26(5).
- [14]Ji Won, Jung,Byung Hoon, Chung,Eung Kweon, Kim,etc.The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery.[J].2015,56.
- [15]Sunil, Ganekal,Ashwini, Nagarajappa.Comparison of morphological and functional endothelial cell changes after cataract surgery: phacoemulsification versus manual small-incision cataract surgery.[J].1900,21(1).